Q-omics provides the consensus-scored MIR6769A profile across patient tissues and cancer cell-line models. MIR6769A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR6769A is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MIR6769A RNA expression shows 12,381 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where MIR6769A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6769A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6769A survival associations across molecular data types. MIR6769A RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6769A RNA expression–survival associations across cancer types. High MIR6769A expression shows unfavorable associations in KIRP, COAD, SKCM and THYM, but favorable associations in BLCA and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR6769A RNA expression.
This table summarizes MIR6769A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6769A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6769A shows lower tumor expression in LUSC and THCA and higher tumor expression in KIRC. The KIRC box plot shows higher MIR6769A RNA expression in tumor versus normal tissue (log2 FC = +0.275, t-test p = .001).
This table shows molecular features associated with MIR6769A in patient tissues and cancer cell lines. In patient samples, MIR6769A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
